Compounds.

Amphihevir {5-cyclopropyl-2-[4-(2-oxooxazolidin-3-yl) piperazine-1-carbonyl]-7-(trifluoromethyl) benzofuran-3-carbonitrile} and its soft capsules were prepared by Changzhou Yinsheng Pharmaceutical Company, Changzhou, Jiangsu Province, China, the sponsor of the clinical trials. The company also provided fopitasvir and its tablets for use as the novel anti-HCV NS5A clinical compound. Daclatasvir, entecavir, and BMS-433771 were synthesized by WuXi AppTec (Shanghai) Co., Ltd., Shanghai, China. Telaprevir and sofosbuvir were bought from Shanghai Haoyuan Biotech Co., Ltd. Alpha interferon (IFN-α), ribavirin, paclitaxel, pleconaril, and acyclovir were purchased from Sigma, Shanghai, China. AG7088 was purchased from Axon Medchem BV, Shanghai, China. Oseltamivir was purchased from TRC, Massachusetts, USA. Reference materials, such as histamine, pyrilamine maleate salt, (±)-SKF-38393, etc., for testing GPCR selection were purchased from Sigma. Staurosporine was purchased from LC Laboratories, Massachusetts, USA. Positive reference compounds for GPCR selectivity studies were purchased from Sigma.